Eliminate Bottlenecks with a Complete Testing Platform
This IO toolkit offers a complete suite of platforms including in vitro 2D/3D assays, pharmacology studies, in vivo efficacy models, and multiomics analysis. Designed to support precise immunotherapy development, it enables comprehensive target evaluation, efficacy testing, and biomarker discovery.
Streamline Immuno-Oncology Development: From In Vitro Insights to In Vivo Success
Make key decisions in a timely and cost-effective manner about the progression of your preclinical development program with cell line-derived xenograft (CDX) models.
Discover homografts derived from immortalized mouse cancer cell lines with fully competent immunity for assessing single agent and combination immunotherapies.
Harness the human immune system against human tumors with human hematopoietic stem cell (HSC) engraftment of patient-derived xenograft models.
Explore a simple alternative to the full stem cell reconstitution approach that allows you to evaluate your immunotherapy within a human tumor microenvironment.
Utilize the XenoBase®, the world’s largest commercial database of well-characterized cell lines to choose the correct cell lines for in vitro evaluation of your novel molecules.
Incorporate the most translatable 3D in vitro models available into your oncology drug development programs with our exclusive Hubrecht Organoid Technology (HUB) licence.
